GSI characterized the acquisition as just one step in a "medical component market strategy, which has been in process for over a year," but also as complementary to GSI's existing lines of medical products. In a press release, the company noted that it has a "number of shared customers [with NDS], which we expect will strengthen the Company's key OEM customer relationships."
Going forward, the company says it expects "nearly 40%" of its revenues to come from the medical market. The NDS transaction in particular is expected to produce $80 million in annual revenue and to be accretive to GSI's earnings in 2013.
Shares of GSI rose 10.3% on the news to $9.34.